Nurix Therapeutics Inc (NASDAQ:NRIX) stock is up 15.7% to trade at $16.94, after the biotech company announced a collaboration and licensing agreement with Roche for blood cancer treatment bexobrutideg. The deal includes a $700 million upfront payment to Nurix, with the company eligible to receive up to $1.6 billion in additional milestone payments. The two firms will jointly commercialize the treatment in the United States, with Phase 3 trials expected to begin later this summer.
Should these gains hold, NRIX will snap a five-day losing streak, and recover a good portion of its 22% year-to-date deficit. On Friday, the shares closed below their 200-day moving average for the first time since October.
Some of today's gains could be attributed to short covering. The 18.63 million shares sold short account for 19.78% of Nurix's available float, representing more than 16 days' worth of pent-up buying power at the stock's average daily trading volume.
| Nov-11 | |
| Nov-10 | |
| Nov-05 | |
| Nov-04 | |
| Nov-04 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Oct-15 |
Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs
NRIX +5.41%
The Wall Street Journal
|
| Oct-12 | |
| Oct-12 | |
| Oct-07 | |
| Oct-05 | |
| Sep-29 | |
| Sep-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite